Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

11,404

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

Cell culture-derived influenza vaccine

One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.

BIOLOGICAL

Egg-derived influenza virus vaccine

One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.

BIOLOGICAL

Placebo

One dose (0.5 mL) of phosphate buffered solution.

Trial Locations (56)

13760

Site 5, Endwell

13901

Site 10, Binghamton

15140

Site 22, Lahti

20520

Site 24, Turku

22105

Site 6, Burke

27103

Site 16, Winston-Salem

28120

Site 23, Pori

29621

Site 12, Anderson

33024

Site 15, Pembroke Pines

33100

Site 21, Tampere

33143

Site 17, South Miami

40004

Site 2, Bardstown

48600

Site 34, Kotka

60100

Site 32, Seinäjoki

63140

Site 1, St Louis

66219

Site 13, Lenexa

67100

Site 35, Kokkola

70100

Site 30, Kuopio

75234

Site 8, Dallas

78705

Site 9, Austin

80212

Site 14, Denver

84109

Site 7, Salt Lake City

84121

Site 3, Salt Lake City

90100

Site 31, Oulu

08817

Site 4, Edison

02886

Site 11, Warwick

02100

Site 25, Espoo

00100

Site 26, Helsinki

00930

Site 27, Helsinki

04400

Site 33, Järvenpää

01300

Site 28, Vantaa

01600

Site 29, Vantaa

85-316

Site 49, Bydgoszcz

26-200

Site 62, Gmina Końskie

88-140

Site 53, Gniewkowo

40-084

Site 59, Katowice

25-711

Site 63, Kielce

30-510

Site 57, Krakow

30-969

Site 41, Krakow

31-115

Site 43, Krakow

31-503

Site 42, Krakow

31-832

Site 50, Krakow

21 - 100

Site 44, Lubartów

20-044

Site 45, Lublin

56-400

Site 65, Oleśnica

10-117

Site 47, Olsztyn

10-295

Site 48, Olsztyn

10-461

Site 46, Olsztyn

32-052

Site 58, Radziszów

41-703

Site 61, Ruda Śląska

35-324

Site 60, Rzeszów

02-777

Site 52, Warsaw

87-200

Site 54, Wąbrzeźno

43-365

Site 55, Wilkowice

51-312

Site 64, Wroclaw

90-302

Site 51, Łodź

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT00630331 - Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter